Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.

Won HR, Lee DH, Yeon SK, Ryu HW, Kim GW, Kwon SH.

Int J Oncol. 2019 Aug;55(2):499-512. doi: 10.3892/ijo.2019.4828. Epub 2019 Jun 20.

PMID:
31268156
2.

Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease.

Park JH, Ju YH, Choi JW, Song HJ, Jang BK, Woo J, Chun H, Kim HJ, Shin SJ, Yarishkin O, Jo S, Park M, Yeon SK, Kim S, Kim J, Nam MH, Londhe AM, Kim J, Cho SJ, Cho S, Lee C, Hwang SY, Kim SW, Oh SJ, Cho J, Pae AN, Lee CJ, Park KD.

Sci Adv. 2019 Mar 20;5(3):eaav0316. doi: 10.1126/sciadv.aav0316. eCollection 2019 Mar.

3.

A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.

Won HR, Ryu HW, Shin DH, Yeon SK, Lee DH, Kwon SH.

Mol Carcinog. 2018 Oct;57(10):1383-1395. doi: 10.1002/mc.22852. Epub 2018 Jun 22.

PMID:
29917295
4.

Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.

Yeon SK, Choi JW, Park JH, Lee YR, Kim HJ, Shin SJ, Jang BK, Kim S, Bahn YS, Han G, Lee YS, Pae AN, Park KD.

Bioorg Med Chem. 2018 Jan 1;26(1):232-244. doi: 10.1016/j.bmc.2017.11.036. Epub 2017 Nov 24.

PMID:
29198609
5.

CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.

Moutal A, Yang X, Li W, Gilbraith KB, Luo S, Cai S, François-Moutal L, Chew LA, Yeon SK, Bellampalli SS, Qu C, Xie JY, Ibrahim MM, Khanna M, Park KD, Porreca F, Khanna R.

Pain. 2017 Dec;158(12):2301-2319. doi: 10.1097/j.pain.0000000000001002.

6.

CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation.

Moutal A, Villa LS, Yeon SK, Householder KT, Park KD, Sirianni RW, Khanna R.

Mol Neurobiol. 2018 May;55(5):4403-4416. doi: 10.1007/s12035-017-0653-9. Epub 2017 Jun 28.

7.

(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.

Moutal A, Chew LA, Yang X, Wang Y, Yeon SK, Telemi E, Meroueh S, Park KD, Shrinivasan R, Gilbraith KB, Qu C, Xie JY, Patwardhan A, Vanderah TW, Khanna M, Porreca F, Khanna R.

Pain. 2016 Jul;157(7):1448-63. doi: 10.1097/j.pain.0000000000000555.

8.

Screening, Synthesis, and In Vitro Evaluation of Vinyl Sulfones as Inhibitors of Complement-Dependent Cytotoxicity in Neuromyelitis Optica.

Ju EJ, Yeon SK, Park JH, Cheon SY, Choi JW, Ha T, Jang BK, Kim S, Kang YG, Hwang H, Cho SJ, Cheong E, Bahn YS, Pae AN, Kim SM, Park KD.

ChemMedChem. 2016 Feb 17;11(4):377-81. doi: 10.1002/cmdc.201500546. Epub 2016 Jan 25.

PMID:
26804736
9.

Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.

Choi JW, Jang BK, Cho NC, Park JH, Yeon SK, Ju EJ, Lee YS, Han G, Pae AN, Kim DJ, Park KD.

Bioorg Med Chem. 2015 Oct 1;23(19):6486-96. doi: 10.1016/j.bmc.2015.08.012. Epub 2015 Aug 19.

PMID:
26337020
10.

(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.

Moutal A, François-Moutal L, Perez-Miller S, Cottier K, Chew LA, Yeon SK, Dai J, Park KD, Khanna M, Khanna R.

Mol Neurobiol. 2016 Apr;53(3):1959-1976. doi: 10.1007/s12035-015-9141-2. Epub 2015 Apr 7.

PMID:
25846820
11.

Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson's disease therapy.

Woo SY, Kim JH, Moon MK, Han SH, Yeon SK, Choi JW, Jang BK, Song HJ, Kang YG, Kim JW, Lee J, Kim DJ, Hwang O, Park KD.

J Med Chem. 2014 Feb 27;57(4):1473-87. doi: 10.1021/jm401788m. Epub 2014 Feb 5.

PMID:
24467268

Supplemental Content

Support Center